Literature DB >> 26131191

RhoBTB2 (DBC2) functions as a multifunctional tumor suppressor in thyroid cancer cells via mitochondrial apoptotic pathway.

Chuan-Jiang Wang1, Dong Yang1, Ying-Wei Luo1.   

Abstract

Thyroid cancer is the most common endocrine malignancy worldwide. Tumor suppressor gene RhoBTB2 (also known as Deleted in Breast Cancer 2, DBC2) was observed in various carcinomas, however, no reports showed the effects of RhoBTB2 on thyroid cancer. In our study, we found that RhoBTB2 decreases proliferation, increases apoptosis, inhibits mobility, and induces mitochondria damage in SW579 cells through increased Bax and decreased Bcl-2 and Bcl-xL protein expression. The effects of RhoBTB2 on SW579 cells were inversed by using butin (an inhibitor of the mitochondrial apoptosis pathway). Our results suggest that RhoBTB2 suppresses the growth of SW579 cells through a mitochondrial apoptosis pathway.

Entities:  

Keywords:  RhoBTB2; apoptosis; mitochondrial apoptotic pathway; mobility; thyroid cancer

Year:  2015        PMID: 26131191      PMCID: PMC4483867     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  The role of Rho GTPases in the regulation of the rearrangement of actin cytoskeleton and cell movement.

Authors:  Rokeya Begum; M S A Nur-E-Kamal; M A Zaman
Journal:  Exp Mol Med       Date:  2004-08-31       Impact factor: 8.718

3.  DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways.

Authors:  Veeraiah Siripurapu; Jennifer Meth; Noriko Kobayashi; Masaaki Hamaguchi
Journal:  J Mol Biol       Date:  2004-12-08       Impact factor: 5.469

Review 4.  Telomerase activity in human cancer.

Authors:  J W Shay; W E Wright
Journal:  Curr Opin Oncol       Date:  1996-01       Impact factor: 3.645

5.  Ectopic expression of RhoBTB2 inhibits migration and invasion of human breast cancer cells.

Authors:  Li-Jun Ling; Chao Lu; Guo-Ping Zhou; Shui Wang
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

6.  Downregulated RhoBTB2 expression contributes to poor outcome in osteosarcoma patients.

Authors:  Zhe Jin; Ya-Xin Han; Xiao-Rui Han
Journal:  Cancer Biother Radiopharm       Date:  2013-06-18       Impact factor: 3.099

7.  Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.

Authors:  Hui Ye; Nisa Pungpravat; Bau-Lin Huang; Lorenzo L Muzio; Maria A Mariggiò; Zugen Chen; David T Wong; Xiaofeng Zhou
Journal:  Cancer Genet Cytogenet       Date:  2007-07-15

8.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

9.  Genetic analysis of the DBC2 gene in gastric cancer.

Authors:  Yong Gu Cho; Byung Joon Choi; Chang Jae Kim; Jae Hwi Song; Cao Zhang; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Acta Oncol       Date:  2007-09-28       Impact factor: 4.089

10.  Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells.

Authors:  Pu Xia; Wen-feng Gou; Jin-jin Wang; Ze-feng Niu; Shuo Chen; Yasuo Takano; Hua-chuan Zheng
Journal:  Cancer Biother Radiopharm       Date:  2013-03-20       Impact factor: 3.099

View more
  2 in total

Review 1.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

Review 2.  Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis.

Authors:  Wei Ji; Francisco Rivero
Journal:  Cells       Date:  2016-06-14       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.